SCHEMBL2177223

SCHEMBL2177223

CC(NC(=O)Cc1ccccc1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.63
CNR2 P34972 7/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
CYP1A2 P05177 1/20 0.59
ALDH1A1 P00352 3/20 0.58
PSMB8 P28062 1/20 0.58
PSMB5 P28074 1/20 0.58
KDM4E B2RXH2 1/20 0.58
CNR1 P21554 1/20 0.57
TSHR P16473 1/20 0.57
HPGD P15428 2/20 0.56
MAPT P10636 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8035990 1.00 POLB (0.63) POLBCNR2MEN1KMT2ACYP1A2
SCHEMBL2177216 1.00 POLB (0.63) POLBCNR2MEN1KMT2ACYP1A2
SCHEMBL15743800 0.87 POLB (0.61) POLBCNR2MEN1KMT2ACYP1A2
SCHEMBL27343284 0.87 POLB (0.61) POLBCNR2MEN1KMT2ACYP1A2
SCHEMBL31416461 0.86 POLB (0.52) POLBCNR2MEN1KMT2ACYP1A2
SCHEMBL6136486 0.86 HPGD (0.58) CNR2MEN1KMT2AALDH1A1PSMB8
SCHEMBL6136490 0.86 HPGD (0.58) CNR2MEN1KMT2AALDH1A1PSMB8
SCHEMBL5842514 0.86 POLB (0.59) POLBCNR2MEN1KMT2ACYP1A2
SCHEMBL9783328 0.85 POLB (0.67) POLBCNR2MEN1KMT2ACYP1A2
SCHEMBL7674546 0.85 POLB (0.67) POLBCNR2MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12566161-B2 Methods and consumer products for detecting a metabolite KIMBERLY-CLARK WORLDWIDE, INC. (US) 2026-03-03 US claimed
US-20240290431-A1 BIOMARKER AND DIAGNOSIS SYSTEM FOR COLORECTAL CANCER DETECTION HANGZHOU CALIBRA DIAGNOSTICS CO LTD (CN) 2024-08-29 US claimed
US-20230402131-A1 BIOMARKER AND DIAGNOSIS SYSTEM FOR COLORECTAL CANCER DETECTION HANGZHOU CALIBRA DIAGNOSTICS CO., LTD. (CN) 2023-12-14 US claimed
US-20230400438-A1 METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE KIMBERLY-CLARK WORLDWIDE, INC. 2023-12-14 US claimed
CN-115436633-A Biomarker for colorectal cancer detection and application thereof 杭州凯莱谱精准医疗检测技术有限公司 2022-12-06 CN claimed
CN-115440375-A Colorectal cancer prediction system and application thereof 杭州凯莱谱精准医疗检测技术有限公司 2022-12-06 CN claimed
CN-114758719-B Colorectal cancer prediction system and application thereof 杭州凯莱谱精准医疗检测技术有限公司 2022-10-21 CN claimed
CN-114755422-B Biomarker for colorectal cancer detection and application thereof 杭州凯莱谱精准医疗检测技术有限公司 2022-10-21 CN claimed
CN-114758719-A Colorectal cancer prediction system and application thereof 杭州凯莱谱精准医疗检测技术有限公司 2022-07-15 CN claimed
CN-114755422-A Biomarker for colorectal cancer detection and application thereof 杭州凯莱谱精准医疗检测技术有限公司 2022-07-15 CN claimed
EP-1047391-A4 ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS GILLETTE CO (US) 2005-01-19 EP claimed
US-20030191119-A1 N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds WU JING (US) 2003-10-09 US claimed
US-20020137743-A1 N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds WU JING (US) 2002-09-26 US claimed
US-6238655-B1 USEFUL IN THE FORMULATION OF DEODORANTS, ANTIPERSPIRANTS, BODY SPRAYS, AND OTHER SKIN TREATMENT COMPOSITIONS. THE GILLETTE COMPANY 2001-05-29 US claimed
EP-1047391-A1 ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS THE GILLETTE COMPANY (US) 2000-11-02 EP claimed
EP-0951464-A1 N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS Elan Pharmaceuticals, Inc. (US) 1999-10-27 EP claimed
WO-1999030679-A1 α-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS THE GILLETTE COMPANY (US) 1999-06-24 WO claimed
WO-1998046599-A1 NOVEL CARBOXAMIDES AS PLATELET AGGREGATION INHIBITORS J. URIACH & CIA. S.A. (ES) 1998-10-22 WO claimed
WO-1998022430-A9 N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS 1998-08-20 WO claimed
WO-1998022430-A1 N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137743-A1 N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds APP, BACE1, IAPP POLB 3668/4885CNR2 1983/4885MEN1 2296/4885
US-12566161-B2 Methods and consumer products for detecting a metabolite SLC6A6, SLC7A11, CTH POLB 2035/4885CNR2 2980/4885MEN1 4783/4885
US-20030191119-A1 N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds APP, BACE1, IAPP POLB 3668/4885CNR2 1983/4885MEN1 2296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.